Ostrom QT, Bauchet L, Davis FG, Deltour I, Fisher JL, et al. The epidemiology of glioma in adults: a “state of the science” review. Neuro-Oncology. 2014;16:896–913.
Article
PubMed
PubMed Central
CAS
Google Scholar
Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66.
Article
PubMed
CAS
Google Scholar
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.
Article
PubMed
CAS
Google Scholar
Palucka K, Banchereau J. Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012;12:265–77.
Article
PubMed
PubMed Central
CAS
Google Scholar
Palucka K, Banchereau J. Dendritic-cell-based therapeutic cancer vaccines. Immunity. 2013;39:38–48.
Article
PubMed
PubMed Central
CAS
Google Scholar
Hsu FJ, Benike C, Fagnoni F, Liles TM, Czerwinski D, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996;2:52–8.
Article
PubMed
CAS
Google Scholar
Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24:3089–94.
Article
PubMed
CAS
Google Scholar
Liau LM, Black KL, Martin NA, Sykes SN, Bronstein JM, et al. Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case report. Neurosurg Focus. 2000;e8:9.
Google Scholar
Kikuchi T, Akasaki Y, Irie M, Homma S, Abe T, et al. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother. 2001;50:337–44.
Article
PubMed
CAS
Google Scholar
Yu JS, Wheeler CJ, Zeltzer PM, Ying H, Finger DN, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res. 2001;61:842–7.
PubMed
CAS
Google Scholar
Wheeler CJ, Black KL, Liu G, Ying H, Yu JS, et al. Thymic CD8+ T cell production strongly influences tumor antigen recognition and age-dependent glioma mortality. J Immunol. 2003;171:4927–33.
Article
PubMed
CAS
Google Scholar
Yamanaka R, Abe T, Yajima N, Tsuchiya N, Homma J, et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer. 2003;89:1172–9.
Article
PubMed
PubMed Central
CAS
Google Scholar
Caruso DA, Orme LM, Neale AM, Radcliff FJ, Amor GM, et al. Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro-Oncology. 2004;6:236–46.
Article
PubMed
PubMed Central
CAS
Google Scholar
De Vleeschouwer S, Van Calenbergh F, Demaerel P, Flamen P, Rutkowski S, et al. Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report. J Neurosurg. 2004;100:492–7.
PubMed
Google Scholar
Kikuchi T, Akasaki Y, Abe T, Fukuda T, Saotome H, et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother. 2004;27:452–9.
Article
PubMed
CAS
Google Scholar
Rutkowski S, De Vleeschouwer S, Kaempgen E, Wolff JE, Kuhl J, et al. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer. 2004;91:1656–62.
Article
PubMed
PubMed Central
CAS
Google Scholar
Wheeler CJ, Das A, Liu G, Yu JS, Black KL. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res. 2004;10:5316–26.
Article
PubMed
CAS
Google Scholar
Yu JS, Liu G, Ying H, Yong WH, Black KL, et al. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res. 2004;64:4973–9.
Article
PubMed
CAS
Google Scholar
Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005;11:5515–25.
Article
PubMed
CAS
Google Scholar
Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res. 2005;11:4160–7.
Article
PubMed
CAS
Google Scholar
Khan JA, Yaqin S. Dendritic cell therapy with improved outcome in glioma multiforme—a case report. J Zhejiang Univ Sci B. 2006;7:114–7.
Article
PubMed
PubMed Central
Google Scholar
Okada H, Lieberman FS, Walter KA, Lunsford LD, Kondziolka DS, et al. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas. J Transl Med. 2007;5:67.
Article
PubMed
PubMed Central
CAS
Google Scholar
de Vleeschouwer S, Fieuws S, Rutkowski S, Van Calenbergh F, Van Loon J, et al. Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. Clin Cancer Res. 2008;14:3098–104.
Article
PubMed
CAS
Google Scholar
Walker DG, Laherty R, Tomlinson FH, Chuah T, Schmidt C. Results of a phase I dendritic cell vaccine trial for malignant astrocytoma: potential interaction with adjuvant chemotherapy. J Clin Neurosci. 2008;15:114–21.
Article
PubMed
CAS
Google Scholar
Wheeler CJ, Black KL, Liu G, Mazer M, Zhang XX, et al. Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients. Cancer Res. 2008;68:5955–64.
Article
PubMed
CAS
Google Scholar
Sampson JH, Archer GE, Mitchell DA, Heimberger AB, Herndon JE, 2nd, , et al. An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme. Mol Cancer Ther 2009;8:2773–2779.
Article
PubMed
PubMed Central
CAS
Google Scholar
Ardon H, De Vleeschouwer S, Van Calenbergh F, Claes L, Kramm CM, et al. Adjuvant dendritic cell-based tumour vaccination for children with malignant brain tumours. Pediatr Blood Cancer. 2010;54:519–25.
PubMed
Google Scholar
Ardon H, Van Gool S, Lopes IS, Maes W, Sciot R, et al. Integration of autologous dendritic cell-based immunotherapy in the primary treatment for patients with newly diagnosed glioblastoma multiforme: a pilot study. J Neuro-Oncol. 2010;99:261–72.
Article
CAS
Google Scholar
Chang CN, Huang YC, Yang DM, Kikuta K, Wei KJ, et al. A phase I/II clinical trial investigating the adverse and therapeutic effects of a postoperative autologous dendritic cell tumor vaccine in patients with malignant glioma. J Clin Neurosci. 2011;18:1048–54.
Article
PubMed
CAS
Google Scholar
Fadul CE, Fisher JL, Hampton TH, Lallana EC, Li Z, et al. Immune response in patients with newly diagnosed glioblastoma multiforme treated with intranodal autologous tumor lysate-dendritic cell vaccination after radiation chemotherapy. J Immunother. 2011;34:382–9.
Article
PubMed
PubMed Central
CAS
Google Scholar
Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, et al. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol. 2011;29:330–6.
Article
PubMed
CAS
Google Scholar
Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, et al. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res. 2011;17:1603–15.
Article
PubMed
CAS
Google Scholar
Akiyama Y, Oshita C, Kume A, Iizuka A, Miyata H, et al. alpha-type-1 polarized dendritic cell-based vaccination in recurrent high-grade glioma: a phase I clinical trial. BMC Cancer. 2012;12:623.
Article
PubMed
PubMed Central
CAS
Google Scholar
Ardon H, Van Gool SW, Verschuere T, Maes W, Fieuws S, et al. Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. Cancer Immunol Immunother. 2012;61:2033–44.
Article
PubMed
CAS
Google Scholar
Cho DY, Yang WK, Lee HC, Hsu DM, Lin HL, et al. Adjuvant immunotherapy with whole-cell lysate dendritic cells vaccine for glioblastoma multiforme: a phase II clinical trial. World Neurosurg. 2012;77:736–44.
Article
PubMed
Google Scholar
Iwami K, Shimato S, Ohno M, Okada H, Nakahara N, et al. Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor alpha2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele. Cytotherapy. 2012;14:733–42.
Article
PubMed
CAS
Google Scholar
Jie X, Hua L, Jiang W, Feng F, Feng G, et al. Clinical application of a dendritic cell vaccine raised against heat-shocked glioblastoma. Cell Biochem Biophys. 2012;62:91–9.
Article
PubMed
CAS
Google Scholar
Valle RD, de Cerio AL, Inoges S, Tejada S, Pastor F, et al. Dendritic cell vaccination in glioblastoma after fluorescence-guided resection. World J Clin Oncol. 2012;3:142–9.
Article
PubMed
PubMed Central
Google Scholar
Phuphanich S, Wheeler CJ, Rudnick JD, Mazer M, Wang H, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients with newly diagnosed glioblastoma. Cancer Immunol Immunother. 2013;62:125–35.
Article
PubMed
CAS
Google Scholar
Vik-Mo EO, Nyakas M, Mikkelsen BV, Moe MC, Due-Tonnesen P, et al. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma. Cancer Immunol Immunother. 2013;62:1499–509.
Article
PubMed
PubMed Central
CAS
Google Scholar
Olin MR, Low W, McKenna DH, Haines SJ, Dahlheimer T, et al. Vaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response. J Immunother Cancer. 2014;2:4.
Article
PubMed
PubMed Central
Google Scholar
Hunn MK, Bauer E, Wood CE, Gasser O, Dzhelali M, et al. Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme. J Neuro-Oncol. 2015;121:319–29.
Article
CAS
Google Scholar
Mitchell DA, Batich KA, Gunn MD, Huang MN, Sanchez-Perez L, et al. Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. Nature. 2015;519:366–9.
Article
PubMed
PubMed Central
CAS
Google Scholar
Sakai K, Shimodaira S, Maejima S, Udagawa N, Sano K, et al. Dendritic cell-based immunotherapy targeting Wilms’ tumor 1 in patients with recurrent malignant glioma. J Neurosurg. 2015;123(4):989–97.
Akasaki Y, Kikuchi T, Homma S, Koido S, Ohkusa T, et al. Phase I/II trial of combination of temozolomide chemotherapy and immunotherapy with fusions of dendritic and glioma cells in patients with glioblastoma. Cancer Immunol Immunother. 2016;65:1499–509.
Article
PubMed
CAS
Google Scholar
Inoges S, Tejada S, de Cerio AL, Gallego Perez-Larraya J, Espinos J, et al. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients. J Transl Med. 2017;15:104.
Article
PubMed
PubMed Central
CAS
Google Scholar
Cao JX, Zhang XY, Liu JL, Li D, Li JL, et al. Clinical efficacy of tumor antigen-pulsed DC treatment for high-grade glioma patients: evidence from a meta-analysis. PLoS One. 2014;9:e107173.
Article
PubMed
PubMed Central
CAS
Google Scholar
Kim CH, Woo SJ, Park JS, Kim HS, Park MY, et al. Enhanced antitumour immunity by combined use of temozolomide and TAT-survivin pulsed dendritic cells in a murine glioma. Immunology. 2007;122:615–22.
Article
PubMed
PubMed Central
CAS
Google Scholar
Park SD, Kim CH, Kim CK, Park JA, Sohn HJ, et al. Cross-priming by temozolomide enhances antitumor immunity of dendritic cell vaccination in murine brain tumor model. Vaccine. 2007;25:3485–91.
Article
PubMed
CAS
Google Scholar
Kim TG, Kim CH, Park JS, Park SD, Kim CK, et al. Immunological factors relating to the antitumor effect of temozolomide chemoimmunotherapy in a murine glioma model. Clin Vaccine Immunol. 2010;17:143–53.
Article
PubMed
CAS
Google Scholar
Banissi C, Ghiringhelli F, Chen L, Carpentier AF. Treg depletion with a low-dose metronomic temozolomide regimen in a rat glioma model. Cancer Immunol Immunother. 2009;58:1627–34.
Article
PubMed
CAS
Google Scholar
Jordan JT, Sun W, Hussain SF, DeAngulo G, Prabhu SS, et al. Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy. Cancer Immunol Immunother. 2008;57:123–31.
Article
PubMed
CAS
Google Scholar
Sampson JH, Aldape KD, Archer GE, Coan A, Desjardins A, et al. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro-Oncology. 2011;13:324–33.
Article
PubMed
CAS
Google Scholar
Galea I, Bernardes-Silva M, Forse PA, van Rooijen N, Liblau RS, et al. An antigen-specific pathway for CD8 T cells across the blood-brain barrier. J Exp Med. 2007;204:2023–30.
Article
PubMed
PubMed Central
CAS
Google Scholar
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131:803–20.
Article
PubMed
Google Scholar
Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003.
Article
PubMed
CAS
Google Scholar
Stummer W, Pichlmeier U, Meinel T, Wiestler OD, Zanella F, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial. Lancet Oncol. 2006;7:392–401.
Article
PubMed
CAS
Google Scholar
DeMets DL, Lan KK. Interim analysis: the alpha spending function approach. Stat Med. 1994;13:1341–52.
Article
PubMed
CAS
Google Scholar
Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1963–72.
Article
PubMed
Google Scholar
Okada H, Weller M, Huang R, Finocchiaro G, Gilbert MR, et al. Immunotherapy response assessment in neuro-oncology: a report of the RANO working group. Lancet Oncol. 2015;16:e534–42.
Article
PubMed
PubMed Central
Google Scholar
Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–98.
Article
PubMed
CAS
Google Scholar
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.
Article
PubMed
CAS
Google Scholar
Taphoorn MJ, Claassens L, Aaronson NK, Coens C, Mauer M, et al. An international validation study of the EORTC brain cancer module (EORTC QLQ-BN20) for assessing health-related quality of life and symptoms in brain cancer patients. Eur J Cancer. 2010;46:1033–40.
Article
PubMed
Google Scholar
Mehnert A, Müller D, Lehmann C, Koch U. Die deutsche Version des NCCN Distress-Thermometers. Empirische Prüfung eines Screening-Instruments zur Erfassung psychosozialer Belastung bei Krebspatienten. Zeitschrift Psychiatr Psychol Psychother. 2006;54:213–23.
Google Scholar
Herrmann C, Buss U, Snaith RP. HADS-D: Hospital Anxiety and Depression Scale—Deutsche Version; Ein Fragebogen zur Erfassung von Angst und Depressivitäit in der somatischen Medizin. Bern: Hans Huber Verlag; 1995.
Google Scholar
Rapp M, Ozcan Z, Steiger HJ, Wernet P, Sabel MC, et al. Cellular immunity of patients with malignant glioma: prerequisites for dendritic cell vaccination immunotherapy. J Neurosurg. 2006;105:41–50.
Article
PubMed
CAS
Google Scholar
Sorg RV, Ozcan Z, Brefort T, Fischer J, Ackermann R, et al. Clinical-scale generation of dendritic cells in a closed system. J Immunother. 2003;26:374–83.
Article
PubMed
Google Scholar
Jonuleit H, Kuhn U, Muller G, Steinbrink K, Paragnik L, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol. 1997;27:3135–42.
Article
PubMed
CAS
Google Scholar
Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol. 2006;24:2563–9.
Article
PubMed
CAS
Google Scholar
De Vleeschouwer S, Ardon H, Van Calenbergh F, Sciot R, Wilms G, et al. Stratification according to HGG-IMMUNO RPA model predicts outcome in a large group of patients with relapsed malignant glioma treated by adjuvant postoperative dendritic cell vaccination. Cancer Immunol Immunother. 2012;61:2105–12.
Article
PubMed
CAS
Google Scholar
Calzascia T, Di Berardino-Besson W, Wilmotte R, Masson F, de Tribolet N, et al. Cutting edge: cross-presentation as a mechanism for efficient recruitment of tumor-specific CTL to the brain. J Immunol. 2003;171:2187–91.
Article
PubMed
CAS
Google Scholar
Masson F, Calzascia T, Di Berardino-Besson W, de Tribolet N, Dietrich PY, et al. Brain microenvironment promotes the final functional maturation of tumor-specific effector CD8+ T cells. J Immunol. 2007;179:845–53.
Article
PubMed
CAS
Google Scholar
Maes W, Van Gool SW. Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model. Cancer Immunol Immunother. 2011;60:153–60.
Article
PubMed
CAS
Google Scholar
Pellegatta S, Poliani PL, Corno D, Grisoli M, Cusimano M, et al. Dendritic cells pulsed with glioma lysates induce immunity against syngeneic intracranial gliomas and increase survival of tumor-bearing mice. Neurol Res. 2006;28:527–31.
Article
PubMed
CAS
Google Scholar
Ni HT, Spellman SR, Jean WC, Hall WA, Low WC. Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas. J Neuro-Oncol. 2001;51:1–9.
Article
CAS
Google Scholar
Liau LM, Black KL, Prins RM, Sykes SN, DiPatre PL, et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg. 1999;90:1115–24.
Article
PubMed
CAS
Google Scholar
Heimberger AB, Crotty LE, Archer GE, McLendon RE, Friedman A, et al. Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol. 2000;103:16–25.
Article
PubMed
CAS
Google Scholar
Magana-Maldonado R, Chavez-Cortez EG, Olascoaga-Arellano NK, Lopez-Mejia M, Maldonado-Leal FM, et al. Immunological evasion in glioblastoma. Biomed Res Int. 2016;2016:7487313.
Article
PubMed
PubMed Central
CAS
Google Scholar
Razavi SM, Lee KE, Jin BE, Aujla PS, Gholamin S, et al. Immune evasion strategies of glioblastoma. Front Surg. 2016;3:11.
Article
PubMed
PubMed Central
Google Scholar
Fecci PE, Mitchell DA, Whitesides JF, Xie W, Friedman AH, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 2006;66:3294–302.
Article
PubMed
CAS
Google Scholar
Dix AR, Brooks WH, Roszman TL, Morford LA. Immune defects observed in patients with primary malignant brain tumors. J Neuroimmunol. 1999;100:216–32.
Article
PubMed
CAS
Google Scholar
Morford LA, Elliott LH, Carlson SL, Brooks WH, Roszman TL. T cell receptor-mediated signaling is defective in T cells obtained from patients with primary intracranial tumors. J Immunol. 1997;159:4415–25.
PubMed
CAS
Google Scholar
Brooks WH, Latta RB, Mahaley MS, Roszman TL, Dudka L, et al. Immunobiology of primary intracranial tumors. Part 5: correlation of a lymphocyte index and clinical status. J Neurosurg. 1981;54:331–7.
Article
PubMed
CAS
Google Scholar
Braun DP, Penn RD, Flannery AM, Harris JE. Immunoregulatory cell function in peripheral blood leukocytes of patients with intracranial gliomas. Neurosurgery. 1982;10:203–9.
PubMed
CAS
Google Scholar
Grauer OM, Nierkens S, Bennink E, Toonen LW, Boon L, et al. CD4+FoxP3+ regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer. 2007;121:95–105.
Article
PubMed
CAS
Google Scholar
Grauer OM, Sutmuller RP, van Maren W, Jacobs JF, Bennink E, et al. Elimination of regulatory T cells is essential for an effective vaccination with tumor lysate-pulsed dendritic cells in a murine glioma model. Int J Cancer. 2008;122:1794–802.
Article
PubMed
CAS
Google Scholar
Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28:4722–9.
Article
PubMed
PubMed Central
Google Scholar
Calzascia T, Masson F, Di Berardino-Besson W, Contassot E, Wilmotte R, et al. Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity. 2005;22:175–84.
Article
PubMed
CAS
Google Scholar
Neller MA, Lopez JA, Schmidt CW. Antigens for cancer immunotherapy. Semin Immunol. 2008;20:286–95.
Article
PubMed
CAS
Google Scholar
Nishimura T, Iwakabe K, Sekimoto M, Ohmi Y, Yahata T, et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med. 1999;190:617–27.
Article
PubMed
PubMed Central
CAS
Google Scholar
Sallusto F, Schaerli P, Loetscher P, Schaniel C, Lenig D, et al. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J Immunol. 1998;28:2760–9.
Article
PubMed
CAS
Google Scholar
Caux C, Ait-Yahia S, Chemin K, de Bouteiller O, Dieu-Nosjean MC, et al. Dendritic cell biology and regulation of dendritic cell trafficking by chemokines. Springer Semin Immunopathol. 2000;22:345–69.
Article
PubMed
CAS
Google Scholar
Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH. Induction of tolerance by IL-10-treated dendritic cells. J Immunol. 1997;159:4772–80.
PubMed
CAS
Google Scholar
Grauer O, Poschl P, Lohmeier A, Adema GJ, Bogdahn U. Toll-like receptor triggered dendritic cell maturation and IL-12 secretion are necessary to overcome T-cell inhibition by glioma-associated TGF-beta2. J Neuro-Oncol. 2007;82:151–61.
Article
CAS
Google Scholar
Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol. 2003;21:685–711.
Article
PubMed
CAS
Google Scholar
Dudek AM, Martin S, Garg AD, Agostinis P. Immature, semi-mature, and fully mature dendritic cells: toward a DC-cancer cells interface that augments anticancer immunity. Front Immunol. 2013;4:438.
Article
PubMed
PubMed Central
CAS
Google Scholar
de Vries IJ, Lesterhuis WJ, Scharenborg NM, Engelen LP, Ruiter DJ, et al. Maturation of dendritic cells is a prerequisite for inducing immune responses in advanced melanoma patients. Clin Cancer Res. 2003;9:5091–100.
PubMed
CAS
Google Scholar
Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med. 2001;193:233–8.
Article
PubMed
PubMed Central
CAS
Google Scholar
Eggert AA, Schreurs MW, Boerman OC, Oyen WJ, de Boer AJ, et al. Biodistribution and vaccine efficiency of murine dendritic cells are dependent on the route of administration. Cancer Res. 1999;59:3340–5.
PubMed
CAS
Google Scholar
Eggert AA, van der Voort R, Torensma R, Moulin V, Boerman OC, et al. Analysis of dendritic cell trafficking using EGFP-transgenic mice. Immunol Lett. 2003;89:17–24.
Article
PubMed
CAS
Google Scholar
Morse MA, Coleman RE, Akabani G, Niehaus N, Coleman D, et al. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res. 1999;59:56–8.
PubMed
CAS
Google Scholar
De Vries IJ, Krooshoop DJ, Scharenborg NM, Lesterhuis WJ, Diepstra JH, et al. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 2003;63:12–7.
PubMed
CAS
Google Scholar
Macatonia SE, Knight SC, Edwards AJ, Griffiths S, Fryer P. Localization of antigen on lymph node dendritic cells after exposure to the contact sensitizer fluorescein isothiocyanate. Functional and morphological studies. J Exp Med. 1987;166:1654–67.
Article
PubMed
CAS
Google Scholar
Ruedl C, Koebel P, Bachmann M, Hess M, Karjalainen K. Anatomical origin of dendritic cells determines their life span in peripheral lymph nodes. J Immunol. 2000;165:4910–6.
Article
PubMed
CAS
Google Scholar
Garg S, Oran A, Wajchman J, Sasaki S, Maris CH, et al. Genetic tagging shows increased frequency and longevity of antigen-presenting, skin-derived dendritic cells in vivo. Nat Immunol. 2003;4:907–12.
Article
PubMed
CAS
Google Scholar
Verdijk P, Aarntzen EH, Lesterhuis WJ, Boullart AC, Kok E, et al. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. Clin Cancer Res. 2009;15:2531–40.
Article
PubMed
CAS
Google Scholar
Lesterhuis WJ, de Vries IJ, Schreibelt G, Lambeck AJ, Aarntzen EH, et al. Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. Clin Cancer Res. 2011;17:5725–35.
Article
PubMed
CAS
Google Scholar
Ringel F, Pape H, Sabel M, Krex D, Bock HC, et al. Clinical benefit from resection of recurrent glioblastomas: results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection. Neuro-Oncology. 2016;18:96–104.
Article
PubMed
Google Scholar
Suchorska B, Weller M, Tabatabai G, Senft C, Hau P, et al. Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma-results from the DIRECTOR trial. Neuro-Oncology. 2016;18:549–56.
Article
PubMed
PubMed Central
Google Scholar
Okada H, Kohanbash G, Zhu X, Kastenhuber ER, Hoji A, et al. Immunotherapeutic approaches for glioma. Crit Rev Immunol. 2009;29:1–42.
Article
PubMed
PubMed Central
CAS
Google Scholar
Grauer OM, Wesseling P, Adema GJ. Immunotherapy of diffuse gliomas: biological background, current status and future developments. Brain Pathol. 2009;19:674–93.
Article
PubMed
CAS
Google Scholar
Dubinski D, Wolfer J, Hasselblatt M, Schneider-Hohendorf T, Bogdahn U, et al. CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients. Neuro-Oncology. 2015;18:807–18.
Article
PubMed
PubMed Central
CAS
Google Scholar
Fong B, Jin R, Wang X, Safaee M, Lisiero DN, et al. Monitoring of regulatory T cell frequencies and expression of CTLA-4 on T cells, before and after DC vaccination, can predict survival in GBM patients. PLoS One. 2012;7:e32614.
Article
PubMed
PubMed Central
CAS
Google Scholar
Jacobs JF, Idema AJ, Bol KF, Nierkens S, Grauer OM, et al. Regulatory T cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro-Oncology. 2009;11:394–402.
Article
PubMed
PubMed Central
CAS
Google Scholar
Betts MR, Brenchley JM, Price DA, De Rosa SC, Douek DC, et al. Sensitive and viable identification of antigen-specific CD8+ T cells by a flow cytometric assay for degranulation. J Immunol Methods. 2003;281:65–78.
Article
PubMed
CAS
Google Scholar
Dutoit V, Herold-Mende C, Hilf N, Schoor O, Beckhove P, et al. Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain. 2012;135:1042–54.
Article
PubMed
Google Scholar
Pollack IF, Jakacki RI, Butterfield LH, Hamilton RL, Panigrahy A, et al. Immune responses and outcome after vaccination with glioma-associated antigen peptides and poly-ICLC in a pilot study for pediatric recurrent low-grade gliomas. Neuro-Oncology. 2016;18:1157–68.
Article
PubMed
PubMed Central
CAS
Google Scholar